Edition:
India

Repros Therapeutics Inc (RPRX.OQ)

RPRX.OQ on NASDAQ Stock Exchange Capital Market

0.67USD
19 Jan 2018
Change (% chg)

$0.00 (+0.45%)
Prev Close
$0.66
Open
$0.66
Day's High
$0.67
Day's Low
$0.66
Volume
29,400
Avg. Vol
250,945
52-wk High
$1.55
52-wk Low
$0.26

Chart for

About

Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally... (more)
No analyst recommendations are available for .

Overall

Beta: 0.40
Market Cap(Mil.): $19.94
Shares Outstanding(Mil.): 37.62
Dividend: --
Yield (%): --

Financials

BRIEF-MMCAP International Reports An 8.48 Pct Passive Stake In Repros Therapeutics

* MMCAP INTERNATIONAL INC SPC REPORTS A 8.48 PCT PASSIVE STAKE IN AS OF DEC 12, 2017 - SEC FILING Source text : (http://bit.ly/2CtINer) Further company coverage:

03 Jan 2018

BRIEF-Repros Says Received EMA Feedback That Negative Opinion Is Likely To Be Received In Jan 2018

* REPROS THERAPEUTICS INC.® RECEIVES FEEDBACK FOLLOWING AN ORAL EXPLANATION WITH THE EUROPEAN MEDICINES AGENCY

16 Dec 2017

BRIEF-Repros Therapeutics Announces Acquisition By Allergan

* REPROS THERAPEUTICS INC.® ANNOUNCES ACQUISITION BY ALLERGAN PLC

12 Dec 2017

BRIEF-Repros Therapeutics Q3 loss per share $0.04

* Repros Therapeutics Inc.® reports third quarter 2017 financial results

13 Nov 2017

BRIEF-Rosalind Advisors reports 5.7 pct stake in Repros Therapeutics

* Rosalind Advisors Inc reports 5.7 percent passive stake in Repros Therapeutics Inc as of July 20 - SEC filing Source text: (http://bit.ly/2gXOAhU) Further company coverage:

25 Jul 2017

Earnings vs. Estimates